哈尔滨医科大学附属肿瘤医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma0 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma58 篇牵头论文
- 胃癌Stomach cancer66 篇牵头论文
- 肺癌Lung cancer156 篇牵头论文
- 胰腺癌Pancreatic cancer27 篇牵头论文
- 乳腺癌Breast cancer168 篇牵头论文牵头 1 项开放试验
- 胶质瘤Glioma14 篇牵头论文
- 骨肉瘤Osteosarcoma2 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma6 篇牵头论文
- 淋巴瘤Lymphoma26 篇牵头论文
- 范可尼贫血Fanconi anaemia0 篇牵头论文
- IgA 肾病IgA nephropathy0 篇牵头论文
未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年没有牵头鼻咽癌的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
PubMed 以外找到的论文(未计入)2
- Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 1 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2026-08
- 发布
- 登记号
- NCT07700667
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 21 家列出的医院为研究中心十堰、南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、重庆、长春
- 正在招募A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06644781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春
- 即将招募A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- 分期
- II期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07623642
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- Intratumoral and peritumoral heterogeneity based on CT to predict the pathological response after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.
- Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.
- Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma.
- Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression.
- Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
- Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
- Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
- Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma.
- Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis.
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling.
- Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma.
- UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
- Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)32
- 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma
- 272. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS CONVERSION THERAPY FOR LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM STUDY
- 287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY
- 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical
- 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?
- Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study.
- Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research.
- LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study
- Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.
- Tumor Microenvironment-Guided Fine-Tuning of Pathology Foundation Models for Esophageal Squamous Cell Carcinoma Immunotherapy Response Prediction
- 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies
- Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
- 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
- Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Development and validation of a survival prediction model for patients with esophageal squamous cell carcinoma of the thoracic segment with pT1-2 lymph node metastasis
- Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).
- O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
- 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha
- 65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research
- 66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
- CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
- ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
- Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
- Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study
- Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 58 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
这家医院参与的开放试验 13
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募First in Human Study of SIM0610 in Solid Tumors
- 分期
- I期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07348211
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、哈尔滨、沈阳、重庆
- 正在招募A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- 分期
- I/II期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07547553
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、郑州、长春
- 正在招募Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
- 分期
- II/III期
- 开始
- 2025-02
- 发布
- 登记号
- NCT06796803
年龄 18 岁 至 75 岁(登记的条件)
牵头:复旦大学附属中山医院;另有 1 家列出的医院为研究中心上海、哈尔滨
- 正在招募JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- 分期
- II期
- 开始
- 2025-05
- 发布
- 登记号
- NCT06954467
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、合肥、哈尔滨、沈阳、郑州、长沙
- 正在招募Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- 分期
- I期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07176650
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春
- 正在招募NWRD06 DNA Plasmid for HCC After Curative Resection.
- 分期
- II期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07324304
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、哈尔滨、杭州
- 正在招募Phase 2 Study of WGI-0301 for Advanced HCC
- 分期
- II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06309485
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙
- 正在招募A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06427941
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙
- 正在招募Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- 分期
- I/II期
- 开始
- 2021-11
- 发布
- 登记号
- NCT05024214
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、广州、杭州、沈阳、珠海、福州、蚌埠、郑州、长春
- 即将招募The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- 分期
- 未注明
- 开始
- 2026-07
- 发布
- 登记号
- NCT07724951
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属中山医院;另有 6 家列出的医院为研究中心上海、南宁、哈尔滨、广州、青岛
- 即将招募Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
- 分期
- I/II期
- 开始
- 2026-09
- 发布
- 登记号
- NCT07761286
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心哈尔滨
- 即将招募JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- 分期
- III期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07823348
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、哈尔滨
- 即将招募Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- 分期
- 不分期
- 开始
- 2025-06
- 发布
- 登记号
- NCT07010588
年龄 18 岁 至 75 岁(登记的条件)
牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文58
- In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.
- Integrating lesser omentum adipose CT in dual-phase tumor imaging: A multi-label deep learning framework for preoperative microvascular invasion prediction and survival analysis in hepatocellular carcinoma.
- An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC.
- Deep Learning-Based Prediction of Microvascular Invasion and Survival Outcomes in Hepatocellular Carcinoma Using Dual-phase CT Imaging of Tumors and Lesser Omental Adipose: A Multicenter Study.
- Targeted nanosensitizer-augmented sono-immunotherapy with STING agonist to remodel the immune microenvironment in hepatocellular carcinoma.
- Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors.
- Targeting RECQL4 in hepatocellular carcinoma: from prognosis to therapeutic potential.
- TAPP@NBs combined with GSNO to enhance the anti-liver cancer effect of sonodynamic therapy.
- Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study.
- Comparative analysis of metabolome and transcriptomes to explore the inhibited influence of sonodynamic therapy combined with lonidamine on hepatocellular carcinoma.
- The transcription factor HOXB7 significantly enhances the expression of PIGT through the Wnt/β-catenin signaling pathway, thereby promoting the proliferation and deterioration of HCC.
- TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study.
- Macrophage hitchhiking for systematic suppression in postablative multifocal HCC.
- Ultrasound-responsive nanobubble-mediated sonodynamic therapy sensitizes disulfidptosis in the treatment of liver hepatocellular carcinoma.
- NIR-II Light-Actuated Nanomotors for Enhanced Photoimmunotherapy Toward Hepatocellular Carcinoma.
- Reply to the Letter from Qian Ren and Yanjun Wang About the Article, "LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection".
- Three-dimensional morphology scoring of hepatocellular carcinoma stratifies prognosis and immune infiltration.
- SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.
- CsxWO3@NBs as a Multi-Image Guided Photothermal/Photodynamic Combination Therapy Platform for the Treatment of Hepatocellular Carcinoma.
- Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy.
- The mechanism and experimental verification of Ixeris sonchifolia promoting apoptosis of hepatocellular carcinoma based on network pharmacology: Ixeris sonchifolia Induces Hepatocellular Carcinoma Apoptosis via the PI3K/AKT Pathway.
- Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms.
- Clinical prediction of microvascular invasion in hepatocellular carcinoma using an MRI-based graph convolutional network model integrated with nomogram.
- Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.
- LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection.
- Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
- Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
- BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1.
- A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.
- Interleukin-35 expression promotes hepatocellular carcinogenesis by inducing γδ T-cell exhaustion.
- The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.
- Recent advances in natural polysaccharides against hepatocellular carcinoma: A review.
- Sonosensitizer Nanoplatforms Augmented Sonodynamic Therapy-Sensitizing Shikonin-Induced Necroptosis Against Hepatocellular Carcinoma.
- IR-820@NBs Combined with MG-132 Enhances the Anti-Hepatocellular Carcinoma Effect of Sonodynamic Therapy.
- Sono-Immunotherapy Mediated Controllable Composite Nano Fluorescent Probes Reprogram the Immune Microenvironment of Hepatocellular Carcinoma.
- Establishment and Validation of the LI-RADS Morphologic Type II Hepatocellular Carcinoma Early Recurrence Risk Scoring System.
- ZMIZ1 Upregulation of TET3-Mediated Hydroxymethylation Induces M2 Polarization of Kupffer Cells in Hepatocellular Carcinogenesis by Mediating Notch1/c-Myc Signaling.
- Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.
- Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting hepatocellular carcinoma prognosis after radiofrequency ablation.
- Pharmacokinetic analysis of different contrast agents on multiphase enhanced MRI for microvascular invasion: preoperative prediction in hepatocellular carcinoma.
- Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.
- Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
- Lean body mass predicts postoperative liver failure in patients with hepatocellular carcinoma.
- Dose of intra-operative opioids has no impact on recurrence or survival in primary liver cancer.
- A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma.
- Development and validation of four ferroptosis-related gene signatures and their correlations with immune implication in hepatocellular carcinoma.
- A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
- RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC.
- Comparison of 8spheres polyvinyl alcohol microsphere and gelatin sponge particle efficacy for transcatheter arterial chemoembolization in stages A to B patients with hepatocellular carcinoma.
- Dynamic Contrast-Enhanced Ultrasonography with Sonazoid for Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma.
- Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis.
- Value of gadoxetic acid-enhanced MRI for microvascular invasion of small hepatocellular carcinoma: a retrospective study.
- Circ_0004018 suppresses cell proliferation and migration in hepatocellular carcinoma via miR-1197/PTEN/PI3K/AKT signaling pathway.
- Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell progression in hepatocellular carcinoma.
- Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma.
- Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma.
- Oxygen-sufficient lipid nanobubbles combined with UTMD for enhanced sonodynamic therapy of Hep-G2 cells.
- Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
- First in Human Study of SIM0610 in Solid Tumors
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- NWRD06 DNA Plasmid for HCC After Curative Resection.
- Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase 2 Study of WGI-0301 for Advanced HCC
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 66 篇,占 0.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下
这家医院参与的开放试验 16
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- 分期
- III期
- 开始
- 2025-02
- 发布
- 登记号
- NCT06731478
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川
- 正在招募A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- 分期
- III期
- 开始
- 2025-05
- 发布
- 登记号
- NCT06901531
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、西宁、郑州
- 正在招募A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- 分期
- III期
- 开始
- 2025-08
- 发布
- 登记号
- NCT07023315
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、哈尔滨、石家庄、福州
- 正在招募A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07066657
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙
- 正在招募Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
- 分期
- II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07102901
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、郑州
- 正在招募Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- 分期
- II期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07127822
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛
- 正在招募DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- 分期
- II/III期
- 开始
- 2024-02
- 发布
- 登记号
- NCT06221748
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛
- 正在招募Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- 分期
- I/II期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06324357
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春
- 正在招募A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06427941
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙
- 正在招募To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- 分期
- II/III期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06504732
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、沈阳
- 正在招募A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- 分期
- III期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06532006
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、洛阳、石家庄、福州、蚌埠、西宁、郑州、重庆、银川、长春、长沙、青岛
- 正在招募A Phase 2 Clinical Study of ABSK061 and ABSK043
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06632262
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州
- 正在招募A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2024-12
- 发布
- 登记号
- NCT06783569
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、沈阳
- 正在招募Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- 分期
- III期
- 开始
- 2023-04
- 发布
- 登记号
- NCT05918094
年龄 18 岁 至 75 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 7 家列出的医院为研究中心上海、南昌、哈尔滨、大连、广州、成都、武汉、郑州
- 正在招募Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- II期
- 开始
- 2023-11
- 发布
- 登记号
- NCT06155383
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州
- 正在招募Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- 分期
- I期
- 开始
- 2021-06
- 发布
- 登记号
- NCT04900818
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文66
- Noninvasive detection and differentiation of gastric malignancy using cell-free DNA biomarkers.
- Effect of sevoflurane-based or propofol-based anesthesia on acute kidney injury after surgery for gastric cancer: a retrospective propensity score-matched analysis.
- Predictive value of 18F-FDG PET/CT metabolic parameters for gastric cancer patients' microsatellite instability status.
- The prealbumin-CD19+ index predicts surgical survival in patients with GC.
- Sedated and unsedated gastroscopy has no influence on the outcomes of patients with gastric cancer: a retrospective study.
- Enhanced recovery after gastrectomy: updated Meta-analysis of 27 randomized trials (2018-2025).
- A Comprehensive Analysis of the Clinical Significance and Underlying Oncogenic Roles of Specific MMPs in Gastric Carcinoma Reveals their Potential Roles in Prognosis and Therapy.
- Skeletal muscle index combined with IgM predicts prognosis in gastric cancer patients who underwent surgery.
- Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.
- Comparison of Short-Term Outcomes of Robot-Assisted Distal Gastrectomy Using the KangDuo Surgical Robot-01 System and Laparoscopic Gastrectomy.
- Study on the Safety and Effectiveness of Using Modified Tubular Stomach for Sideoverlap Anastomosis in Laparoscopic Proximal Gastrectomy.
- Effects of enhanced recovery after surgery nursing combined with early enteral nutrition on Gastrointestinal function recovery after radical gastrectomy.
- A Polysaccharide-Based Fluorescent Polymer Carrier for Natural Product Delivery and Gastric Cancer Inhibition.
- Metabolic and aging related gene risk score for therapeutic stratification and precision oncology in gastric cancer.
- Nutritional Risk Index (NRI) predicts the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors (PD-1/PD-L1).
- A large histological images dataset of gastric cancer with tumour microenvironment annotation for AI.
- LRP12 promotes gastric cancer progression through AKT/mTOR signaling and M2 macrophage-mediated immunosuppression.
- Integrating psychological and dietary care for patients with advanced gastric cancer undergoing chemotherapy: a randomized controlled trial.
- Clinical application of the KangDuo-Surgical Robot-01 in distal gastrectomy for gastric cancer.
- Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma.
- Machine learning-based reconstruction of prognostic staging for gastric cancer patients with different differentiation grades: A multicenter retrospective study.
- Integrin β5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer.
- Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
- EIF2S2 transcriptionally upregulates HIF1α to promote gastric cancer progression via activating PI3K/AKT/mTOR pathway.
- A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer.
- Preoperative glucose-to-lymphocyte ratio predicts survival in cancer.
- Eco-friendly green synthesis of N‑pyrazole amino chitosan using PEG-400 as an anticancer agent against gastric cancer cells via inhibiting EGFR.
- Normalization weighted combination scores re-evaluate TNM staging of gastric cancer: a retrospective cohort study based on a multicenter database.
- Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer.
- CD3+/CD4+ cells combined with myosteatosis predict the prognosis in patients who underwent gastric cancer surgery.
- Pan-cancer analysis of SERPINE1 with a concentration on immune therapeutic and prognostic in gastric cancer.
- Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration.
- Geriatric nutritional risk index predicts the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.
- EIF4A3-induced circle RNA_ 0001860 promotes growth, invasion, and immune evasion of gastric cancer cells through the miR-618/HMGA2 axis.
- Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy.
- Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.
- Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer.
- Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
- Letter to the editor on"Prognostic significance of preoperative tumor markers combined with controlling nutritional status score in gastric cancer".
- Development and Validation of Tumor Marker Indices in Advanced Gastric Cancer Patients.
- Prognostic importance of the preoperative New-Naples prognostic score for patients with gastric cancer.
- Prediction model based on radiomics and clinical features for preoperative lymphovascular invasion in gastric cancer patients.
- A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.
- The prognostic marker elastin correlates with epithelial-mesenchymal transition and vimentin-positive fibroblasts in gastric cancer.
- Cancer-associated fibroblast expression of glutamine fructose-6-phosphate aminotransferase 2 (GFPT2) is a prognostic marker in gastric cancer.
- Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.
- The Survival Relationship between Preoperative Inflammation Markers and Patients with Special Pathological Types of Gastric Cancer.
- FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer.
- Evaluation of Immune Infiltration Based on Image Plus Helps Predict the Prognosis of Stage III Gastric Cancer Patients with Significantly Different Outcomes in Northeastern China.
- Development and validation of a necroptosis-related gene prognostic score to predict prognosis and efficiency of immunotherapy in gastric cancer.
- Laparoscopic versus open gastrectomy for gastric cancer: A systematic review and meta-analysis of randomized controlled trials.
- Development and validation of an individual alternative splicing prognostic signature in gastric cancer.
- The landscape of alternative splicing reveals novel events associated with tumorigenesis and the immune microenvironment in gastric cancer.
- Proximal gastrectomy with gastric tube reconstruction or jejunal interposition reconstruction in upper-third gastric cancer: which offers better short-term surgical outcomes?
- Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component.
- The Ratio of the Hemoglobin to Red Cell Distribution Width Combined with the Ratio of Platelets to Lymphocytes Can Predict the Survival of Patients with Gastric Cancer Liver Metastasis.
- Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.
- Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer.
- ELF3-AS1 contributes to gastric cancer progression by binding to hnRNPK and induces thrombocytosis in peripheral blood.
- Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.
- Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses.
- Serum CD4 Is Associated with the Infiltration of CD4+T Cells in the Tumor Microenvironment of Gastric Cancer.
- A novel long noncoding RNA, TMEM92-AS1, promotes gastric cancer progression by binding to YBX1 to mediate CCL5.
- In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
- eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.
- Application value of hand-sewn anastomosis in totally laparoscopic total gastrectomy for gastric cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)53
- A Clinical Study for Comparison of the Effects Between Gasless Laparoscopy and Conventional Laparoscopy for Distal Gastric Cancer
- Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer
- Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 156 篇,占 0.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 4 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 69
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- 分期
- II/III期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07063745
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、厦门、哈尔滨、广州、成都、杭州、武汉、沈阳、福州、长沙
- 正在招募Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- 分期
- III期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07195695
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、临沂、北京、南京、南昌、台州、哈尔滨、天津、广州、徐州、成都、扬州、杭州、武汉、济南、石家庄、苏州、郑州、长春、长沙
- 正在招募A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- 分期
- I/II期
- 开始
- 2026-03
- 发布
- 登记号
- NCT07227025
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、广州
- 正在招募A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- 分期
- I/II期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07227597
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南昌、台州、哈尔滨、广州、成都、杭州、江门、福州
- 正在招募A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- 分期
- II期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07253142
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、南宁、合肥、哈尔滨、广州、徐州、新乡、武汉、福州
- 正在招募First in Human Study of SIM0610 in Solid Tumors
- 分期
- I期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07348211
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、哈尔滨、沈阳、重庆
- 正在招募A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- 分期
- I/II期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07367529
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、中山、北京、南京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、扬州、杭州、武汉、西安、长沙
- 正在招募RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- 分期
- III期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07416474
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛
- 正在招募DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- 分期
- III期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07472517
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、宁波、广州、徐州、成都、扬州、杭州、武汉、济南、温州、福州、蚌埠、襄阳、郑州、长沙
- 正在招募A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- 分期
- II期
- 开始
- 2026-07
- 发布
- 登记号
- NCT07622186
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心北京、南京、南宁、南昌、厦门、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、沈阳、济南、福州、襄阳、西安、郑州、重庆、长春、长沙
- 正在招募A Study of DS-3939a in Participants With Solid Tumors
- 分期
- I/II期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07739966
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、台州、哈尔滨、天津、广州、杭州、武汉、济南、郑州、长春、长沙
- 正在招募A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
- 分期
- I/II期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07843940
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、成都
- 正在招募A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- 分期
- II期
- 开始
- 2025-01
- 发布
- 登记号
- NCT06568939
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心临沂、乌鲁木齐、南宁、南昌、哈尔滨、武汉、福州、西安、郑州
- 正在招募Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- 分期
- III期
- 开始
- 2025-02
- 发布
- 登记号
- NCT06712355
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南昌、台州、合肥、哈尔滨、太原、广州、扬州、新乡、杭州、武汉、汕头、济南、温州、石家庄、福州、苏州、蚌埠、襄阳、郑州、重庆、长春
- 正在招募This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- 分期
- III期
- 开始
- 2025-07
- 发布
- 登记号
- NCT06758401
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、常州、广州、徐州、成都、杭州、武汉、洛阳、济南、温州、福州、西安、郑州、长沙
- 正在招募A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-10
- 发布
- 登记号
- NCT06793215
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南昌、南通、合肥、哈尔滨、广州、成都、昆明、杭州、武汉、汕头、济南、蚌埠、长沙
- 正在招募Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-04
- 发布
- 登记号
- NCT06801834
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南京、南昌、厦门、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、深圳、福州、西安、郑州、重庆、长春
- 正在招募A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- 分期
- I期
- 开始
- 2025-02
- 发布
- 登记号
- NCT06839105
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南昌、哈尔滨、广州、昆明、杭州、武汉、沈阳、洛阳、福州、长春、长沙
- 正在招募Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- 分期
- 未注明
- 开始
- 2025-04
- 发布
- 登记号
- NCT06862869
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、兰州、北京、南京、南昌、南通、台州、合肥、哈尔滨、大连、太原、广州、成都、无锡、杭州、武汉、江门、济南、深圳、湛江、石家庄、福州、西安、遵义、重庆、银川、长沙
- 正在招募A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- 分期
- III期
- 开始
- 2025-04
- 发布
- 登记号
- NCT06875310
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、汕头、沈阳、济南、深圳、石家庄、福州、苏州、蚌埠、重庆、长春、长沙
- 正在招募Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06890598
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙
- 正在招募Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-10
- 发布
- 登记号
- NCT06899126
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南昌、合肥、哈尔滨、天津、太原、广州、成都、杭州、武汉、沈阳、济南、襄阳、郑州、重庆、长春、长沙
- 正在招募A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- 分期
- II期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06962865
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心临沂、北京、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、武汉、济南、温州、烟台、石家庄、福州、襄阳、郑州、重庆、长春、长沙
- 正在招募A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- 分期
- III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT07010263
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、安阳、广州、新乡、武汉、江门、沈阳、济南、温州、石家庄、福州、西安、遵义、郑州、重庆、银川、长春、长沙
- 正在招募A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- 分期
- 未注明
- 开始
- 2025-12
- 发布
- 登记号
- NCT07143045
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心佛山、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、太原、广州、成都、扬州、昆明、武汉、沈阳、深圳、福州、郑州、重庆、长春、长沙、青岛
- 正在招募A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- 分期
- III期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07144280
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南宁、南昌、台州、合肥、哈尔滨、常州、广州、徐州、成都、杭州、武汉、济南、福州、西安、郑州、重庆、长沙
- 正在招募A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- 分期
- II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07164170
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、合肥、哈尔滨、广州、成都、武汉、沈阳、福州、西安、郑州
- 正在招募A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- 分期
- I/II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07169994
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、南京、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、沈阳、洛阳、福州、襄阳
- 正在招募A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07182682
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙
- 正在招募Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07185997
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、佛山、北京、南京、南宁、南昌、南通、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、新乡、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、潍坊、石家庄、福州、郑州、重庆、长沙、青岛
- 正在招募A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07217301
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、徐州、成都、新乡、昆明、杭州、沈阳、泸州、济南、温州、石家庄、福州、西安、郑州、重庆、长沙
- 正在招募A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- 分期
- III期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07218146
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、广州、成都、杭州、武汉、济南、石家庄、福州、西安、郑州、长春、长沙
- 正在招募A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- 分期
- I期
- 开始
- 2024-01
- 发布
- 登记号
- NCT06179069
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、广州、成都、武汉、沈阳、西安、郑州、长沙
- 正在招募A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06203210
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、哈尔滨、天津、成都、杭州、武汉、沈阳、济南、烟台、襄阳、郑州、重庆、长沙
- 正在招募A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06345729
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙
- 正在招募A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2024-04
- 发布
- 登记号
- NCT06403735
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、南昌、哈尔滨、昆明
- 正在招募JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- 分期
- III期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06416410
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南京、南宁、台州、哈尔滨、天津、太原、广州、成都、无锡、杭州、武汉、沈阳、济南、深圳、福州、西安、郑州、长沙、青岛
- 正在招募Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- 分期
- III期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06422143
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、台州、哈尔滨、广州、成都、扬州、杭州、武汉、温州、福州、郑州、长春、长沙
- 正在招募A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06427941
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙
- 正在招募A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- 分期
- III期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06452277
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、北京、南京、厦门、台州、哈尔滨、广州、成都、杭州、武汉、济南、福州、长春、长沙
- 正在招募A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- 分期
- II期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06496490
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、佛山、北京、南宁、南昌、哈尔滨、天津、广州、成都、江门、福州、西安、遵义、郑州、长春、长沙
- 正在招募A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- 分期
- III期
- 开始
- 2024-10
- 发布
- 登记号
- NCT06561386
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、新乡、杭州、沈阳、济南、福州、重庆、长沙
- 正在招募A Phase 2 Clinical Study of ABSK061 and ABSK043
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06632262
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、济南、石家庄、襄阳、贵阳、郑州
- 正在招募A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06668103
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、哈尔滨、武汉、长春
- 正在招募Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- 分期
- I/II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT07433283
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、成都、海口、福州、郑州、重庆、长沙
- 正在招募A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- 分期
- I/II期
- 开始
- 2023-06
- 发布
- 登记号
- NCT05789082
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、长沙
- 正在招募A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- 分期
- III期
- 开始
- 2023-11
- 发布
- 登记号
- NCT05920356
年龄 18 岁 至 100 岁(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、昆明、杭州、武汉、汕头、洛阳、济南、潍坊、石家庄、福州、蚌埠、襄阳、西安、郑州、重庆、长春、长沙
- 正在招募A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- 分期
- II期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06010329
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、广州、成都、杭州、武汉、济南、郑州
- 正在招募Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- 分期
- III期
- 开始
- 2023-11
- 发布
- 登记号
- NCT06095583
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、武汉、沈阳、济南、深圳、郑州、重庆、银川、长春、长沙、青岛
- 正在招募A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06119581
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、台州、哈尔滨、天津、宜昌、常州、广州、成都、杭州、武汉、济南、海口、湛江、福州、襄阳、西安、长沙
- 正在招募Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06170788
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙
- 正在招募A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- 分期
- III期
- 开始
- 2022-03
- 发布
- 登记号
- NCT04928846
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙
- 正在招募Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- 分期
- II期
- 开始
- 2022-09
- 发布
- 登记号
- NCT05168566
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、哈尔滨、广州、成都、杭州、武汉、沈阳、蚌埠、郑州、长春、长沙
- 正在招募Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- 分期
- I/II期
- 开始
- 2022-04
- 发布
- 登记号
- NCT05288205
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、临沂、北京、厦门、合肥、呼和浩特、哈尔滨、广州、武汉、沈阳、济南、深圳、福州、郑州、长沙
- 正在招募A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- 分期
- II期
- 开始
- 2022-11
- 发布
- 登记号
- NCT05498428
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、哈尔滨、天津、广州、成都、杭州、武汉、温州、烟台、石家庄、西安
- 正在招募Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- 分期
- I期
- 开始
- 2021-07
- 发布
- 登记号
- NCT04886804
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、南宁、厦门、哈尔滨、广州、杭州、武汉、福州、郑州、长春
- 正在招募A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- 分期
- I期
- 开始
- 2021-08
- 发布
- 登记号
- NCT04913285
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、临沂、哈尔滨
- 正在招募Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- 分期
- I/II期
- 开始
- 2021-09
- 发布
- 登记号
- NCT04930432
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- 分期
- I/II期
- 开始
- 2021-11
- 发布
- 登记号
- NCT05024214
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、太原、广州、昆明、杭州、沈阳、珠海、福州、蚌埠、郑州、长春
- 正在招募First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- 分期
- I/II期
- 开始
- 2021-10
- 发布
- 登记号
- NCT05099172
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、台州、哈尔滨、成都、杭州、济南、福州、长沙
- 正在招募Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- 分期
- II/III期
- 开始
- 2020-12
- 发布
- 登记号
- NCT04613596
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、杭州、武汉、沈阳、济南、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- 分期
- I/II期
- 开始
- 2019-07
- 发布
- 登记号
- NCT04270591
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、石家庄、郑州、长春、长沙
- 即将招募A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- 分期
- I期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07550842
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、台州、哈尔滨、常州、武汉、沈阳、郑州
- 即将招募A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- 分期
- II期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07623642
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨
- 即将招募A Phase 2 Study of ABSK043 Combined With Osimertinib
- 分期
- II期
- 开始
- 2026-08
- 发布
- 登记号
- NCT07710612
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、哈尔滨、太原、广州、杭州、武汉、沈阳
- 即将招募Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- 分期
- I期
- 开始
- 2026-11
- 发布
- 登记号
- NCT07912268
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、南昌、哈尔滨、福州、长沙
- 即将招募Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- 分期
- II期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06885840
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心佛山、兰州、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、济南、西安、郑州、长春、长沙
- 即将招募YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- 分期
- III期
- 开始
- 2023-05
- 发布
- 登记号
- NCT05767892
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、呼和浩特、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长沙、青岛
- 即将招募A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- 分期
- III期
- 开始
- 2023-11
- 发布
- 登记号
- NCT05990127
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、合肥、哈尔滨、天津、太原、广州、徐州、成都、新乡、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、银川、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文156
- Prognostic Value of Multiparameter Biomarkers in Pleural Effusion of Patients With Non-small Cell Lung Cancer for Predicting Survival Outcomes: A Prospective Cohort Study.
- A positive feedback loop between SERPINH1 and MMP-9/TGF-β1 promotes lung adenocarcinoma progression.
- Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.
- Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.
- Pericardial Fat and Primary Tumor Radiomics for Predicting Occult N2 Disease and Survival in Clinical Stage I Non-Small Cell Lung Cancer: Multicenter Study and Biologic Correlation.
- Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma.
- Integrin β8 Facilitates Macrophage Infiltration and Polarization by Regulating CCL5 to Promote LUAD Progression.
- Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort.
- A CT-based radiomics nomogram incorporating adipose tissue to differentiate invasive adenocarcinomas among part-solid pulmonary nodules.
- Deep learning radiomics and mediastinal adipose tissue-based nomogram for preoperative prediction of postoperative brain metastasis risk in non-small cell lung cancer.
- Disease burden of lung cancer attributable to metabolic and behavioral risks in China and globally from 1990 to 2021.
- m6A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma.
- Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.
- MS4A1 regulates M1-polarized tumor-associated macrophage infiltration, angiogenesis, and cancer progression through the HIPPO pathway in lung adenocarcinoma.
- Multimodal Deep Learning Integrating Tumor Radiomics and Mediastinal Adiposity Improves Survival Prediction in Non-Small Cell Lung Cancer: A Prognostic Modeling Study.
- Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC.
- M6A -mediated lncRNA SCIRT stability promotes NSCLC progression through binding to SFPQ and activating the PI3K/Akt pathway.
- Application of random survival forest to establish a nomogram combining clinlabomics-score and clinical data for predicting brain metastasis in primary lung cancer.
- Correlation between radiologic feature and spread through air space in lung solid adenocarcinoma 30.0 mm or less in maximum diameter.
- Prediction of PD-L1 expression in NSCLC patients using PET/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients.
- Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.
- MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis.
- Opsin3 regulates cell proliferation, migration, and apoptosis in lung adenocarcinoma via GPX3 pathway.
- Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization.
- Deep learning model using CT images for longitudinal prediction of benign and malignant ground-glass nodules.
- Post-hoc analysis of real-world retrospective study on neoadjuvant chemotherapy combined with immunotherapy for stage I-III non-small cell lung cancer.
- Advancements in extensive-stage small cell lung cancer therapy: from molecular profiling to the advent of precision oncology.
- The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy.
- A comprehensive prognostic and immunological implications of Gremlin 1 in lung adenocarcinoma.
- Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.
- The role of exosomal PD-L1 in NSCLC immunotherapy.
- RUNX1 promotes NSCLC progression by ACP5/SMAD3-mediated M2 macrophage polarization.
- Development of a machine learning-based prognostic model for survival prediction in patients with lung cancer brain metastases using multicenter clinical data.
- Molecular characterization of breast cancer and multiple primary malignancies: the latest application using unmarked quantitative proteomics.
- Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition.
- Predictive classification of lung cancer pathological based on PET/CT radiomics.
- RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma.
- Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems.
- RBM15 recruits myeloid-derived suppressor cells via the m6A-IGF2BP3/CBR3-AS1/miR-409-3p/CXCL1 axis, facilitating radioresistance in non-small-cell lung cancer.
- Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges.
- Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models.
- 19F MR Imaging of Dule Lung Cancer Models with Two Administration Methods of PFC Nanoparticles.
- RFX2-BNIP3 axis-driven adaptive mitophagy promotes resistance to ACK1-targeted therapy in non-small cell lung cancer.
- RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.
- Dual biomarkers CT-based deep learning model incorporating intrathoracic fat for discriminating benign and malignant pulmonary nodules in multi-center cohorts.
- Landscape of the intratumoral microbiota acting on the tumor immune microenvironment in LUAD and LUSC.
- CT Predictors of Angiolymphatic Invasion in Non-Small Cell Lung Cancer 30 mm or Smaller.
- ZNF184-mediated transcriptional activation of SAE1 drives the cell cycle entry and immune evasion in non-small cell lung cancer.
- In vivo self-assembled bispecific fluorescence probe for early detection of bladder cancer and metastasis.
- Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer.
- Comprehensive profiling of T-cell exhaustion signatures and establishment of a prognostic model in lung adenocarcinoma through integrated RNA-sequencing analysis.
- m6A-Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma.
- Ubiquitin-Specific Protease 22 Plays a Key Role in Increasing Extracellular Vesicle Secretion and Regulating Cell Motility of Lung Adenocarcinoma.
- Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.
- Deep learning-based characterization of pathological subtypes in lung invasive adenocarcinoma utilizing 18F-deoxyglucose positron emission tomography imaging.
- Development and validation of a preoperative CT‑based radiomics nomogram to differentiate tuberculosis granulomas from lung adenocarcinomas: an external validation study.
- Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer.
- FERMT1 promotes cell migration and invasion in non-small cell lung cancer via regulating PKP3-mediated activation of p38 MAPK signaling.
- Dexmedetomidine promotes necroptosis by upregulating PARP1 in non-small cell lung cancer.
- Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.
- An Integrated Nomogram Combining Deep Learning and Radiomics for Predicting Malignancy of Pulmonary Nodules Using CT-Derived Nodules and Adipose Tissue: A Multicenter Study.
- The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.
- A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.
- Multi-scale and multi-view network for lung tumor segmentation.
- METnet: A novel deep learning model predicting MET dysregulation in non-small-cell lung cancer on computed tomography images.
- Predicting the Prognosis of Lung Cancer Patients Treated with Intensitymodulated Radiotherapy based on Radiomic Features.
- MicroRNA-522-3p promotes brain metastasis in non-small cell lung cancer by targeting Tensin 1 and modulating blood-brain barrier permeability.
- Preoperative glucose-to-lymphocyte ratio predicts survival in cancer.
- Multimodal data deep learning method for predicting symptomatic pneumonitis caused by lung cancer radiotherapy combined with immunotherapy.
- Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study.
- Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer.
- Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib in advanced non-small cell lung cancer.
- LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation.
- Combination of the cuproptosis inducer disulfiram and anti‑PD‑L1 abolishes NSCLC resistance by ATP7B to regulate the HIF‑1 signaling pathway.
- Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer.
- Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
- Safety of one 8.5-Fr pigtail catheter for postoperative continuous open gravity drainage after uniportal video-assisted thoracoscopic surgery pneumonectomy.
- Investigation of mediastinal lymph node dissection in clinical stage IA pure-solid non-small cell lung cancer patients.
- Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report.
- Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
- An innovative electrohydrodynamics-driven SERS platform for molecular stratification and treatment monitoring of lung cancer.
- Sleep disturbance as a poor prognostic predictor in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A prospective study.
- Dynamic analysis of predictive biomarkers for radiation therapy efficacy in non-small cell lung cancer patients by next-generation sequencing based on blood specimens.
- SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.
- CT Predictors of Visceral Pleural Invasion in Patients with Non-Small Cell Lung Cancers 30 mm or Smaller.
- Influence of malnutrition according to the glim criteria on the chemotherapy toxicities in patients with advanced lung cancer.
- Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma.
- Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.
- Development and validation of 18F-FDG PET/CT radiomics-based nomogram to predict visceral pleural invasion in solid lung adenocarcinoma.
- The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.
- Sec61γ is a vital protein in the endoplasmic reticulum membrane promoting tumor metastasis and invasion in lung adenocarcinoma.
- LINC00669 promotes lung adenocarcinoma growth by stimulating the Wnt/β-catenin signaling pathway.
- M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway.
- A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer.
- Preoperative small airway dysfunction is associated with skeletal muscle loss in early-stage non-small cell lung cancer.
- Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer.
- IGF2BP3 Worsens Lung Cancer through Modifying Long Non-coding RNA CERS6-AS1/microRNA-1202 Axis.
- miR-4732-3p prevents lung cancer progression via inhibition of the TBX15/TNFSF11 axis.
- Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.
- Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution.
- Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs.
- The significance of spread through air spaces in the prognostic assessment model of stage I lung adenocarcinoma and the exploration of its invasion mechanism.
- Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
- Predictive Value of Gene Databases in Discovering New Biomarkers and New Therapeutic Targets in Lung Cancer.
- Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1.
- The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.
- Sevoflurane attenuates proliferative and migratory activity of lung cancer cells via mediating the microRNA-100-3p/sterol O-Acyltransferase 1 axis.
- Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
- microRNA-651-5p affects the proliferation, migration, and invasion of lung cancer cells by regulating Calmodulin 2 expression.
- NIR-IIb fluorescence-image guided synergistic surgery/starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers.
- Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer.
- Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer.
- Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.
- Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma.
- Surgical Trauma-induced CCL2 Upregulation Mediates Lung Cancer Progression by Promoting Treg Recruitment in Mice and Patients.
- Long noncoding RNA CBR3-AS1 mediates tumorigenesis and radiosensitivity of non-small cell lung cancer through redox and DNA repair by CBR3-AS1 /miR-409-3p/SOD1 axis.
- TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E-cadherin.
- miR-596-3p suppresses brain metastasis of non-small cell lung cancer by modulating YAP1 and IL-8.
- A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma.
- Prognostic Value of Combination of Controlling Nutritional Status and Tumor Marker in Patients with Radical Non-Small-Cell Lung Cancer.
- CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma.
- Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis.
- Knockdown of LINC00511 decreased cisplatin resistance in non-small cell lung cancer by elevating miR-625 level to suppress the expression of leucine rich repeat containing eight volume-regulated anion channel subunit E.
- TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.
- RNA-binding motif protein 10 represses tumor progression through the Wnt/β- catenin pathway in lung adenocarcinoma.
- Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer.
- Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations.
- Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
- Technical aspects and early results of uniportal video-assisted thoracoscopic complex segmentectomy: a 30 case-series study.
- Characterization of the prognostic and diagnostic values of ALKBH family members in non-small cell lung cancer.
- Radiomics combined with clinical features in distinguishing non-calcifying tuberculosis granuloma and lung adenocarcinoma in small pulmonary nodules.
- Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
- Sarcopenia is an independent risk factor for depression in patients with advanced lung cancer.
- Patient-Generated Subjective Global Assessment (PG-SGA) predicts length of hospital stay in lung adenocarcinoma patients.
- MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
- Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.
- Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death.
- Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer.
- High BASP1 Expression is Associated with Poor Prognosis and Promotes Tumor Progression in Human Lung Adenocarcinoma.
- A feedback circuit comprising EHD1 and 14-3-3ζ sustains β-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.
- Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.
- Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
- PIGF and Flt-1 on the surface of macrophages induces the production of TGF-β1 by polarized tumor-associated macrophages to promote lung cancer angiogenesis.
- The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway.
- PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
- The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer.
- Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.
- Stereotactic body radiation therapy for non-small cell lung cancer using the non-coplanar radiation of Cyberknife and Varian linac.
- High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.
- Risk factors for lymph node metastasis and surgical scope in patients with cN0 non-small cell lung cancer: a single-center study in China.
- Engineering of gemcitabine coated nano-graphene oxide sheets for efficient near-infrared radiation mediated in vivo lung cancer photothermal therapy.
- UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma.
- Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
- FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.
- CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.
- High prognostic nutritional index (PNI) as a positive prognostic indicator for non-small cell lung cancer patients with bone metastasis.
中文论文(未计入)3
- [Research Progress on the Protective Effect of Intestinal Flora on Radiation-induced Lung Injury in Thoracic Tumors].
- [Progress of Immune Checkpoint Inhibitors in the Treatment of Advanced Pulmonary Neuroendocrine Tumors].
- [Research Progress of Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)161
- Study of DC-CTL Combined With CIK for Advanced Solid Tumor
- A Study of DS-3939a in Participants With Solid Tumors
- A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- A Phase 2 Study of ABSK043 Combined With Osimertinib
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
- A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- First in Human Study of SIM0610 in Solid Tumors
- A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
- Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
- A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
- A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
- ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
- A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
- Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
- PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
- A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
- Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
- H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC
- Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
- A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
- Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
- Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
- AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
- Bintrafusp Alfa Program Rollover Study
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
- Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
- A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
- A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
- Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer
- Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
- Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
- A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
- A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- Cancer Genome Atlas of China:Lung Cancer
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
- Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
- A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
- A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
- A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
- Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
- A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
- A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China
- Avelumab in First-line NSCLC (JAVELIN Lung 100)
- A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
- Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
- A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
- Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
- Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis
癌症
胰腺癌
Pancreatic cancer2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 3 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下
这家医院参与的开放试验 14
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
- 分期
- I/II期
- 开始
- 2026-07
- 发布
- 登记号
- NCT07640295
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、哈尔滨、太原、杭州、武汉、郑州、长沙
- 正在招募Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
- 分期
- I/II期
- 开始
- 2025-04
- 发布
- 登记号
- NCT06821503
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、天津、沈阳、西安、郑州
- 正在招募A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
- 分期
- III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06953999
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨、杭州
- 正在招募A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07066657
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、长沙
- 正在招募Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
- 分期
- III期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07823049
年龄未注明(登记的条件)
牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、太原、常州、广州、成都、扬州、杭州、武汉、沈阳、福州、西安、郑州、重庆、银川、长春、长沙
- 正在招募A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- 分期
- II/III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06361888
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、深圳、温州、福州、苏州、西安、郑州、重庆、长沙
- 正在招募A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2024-04
- 发布
- 登记号
- NCT06403735
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、南昌、哈尔滨、昆明
- 正在招募Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- 分期
- I/II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT07433283
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、成都、海口、福州、郑州、重庆、长沙
- 正在招募A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- 分期
- II期
- 开始
- 2023-10
- 发布
- 登记号
- NCT06008288
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、福州、西安、郑州、长沙、青岛
- 正在招募A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
- 分期
- II期
- 开始
- 2023-10
- 发布
- 登记号
- NCT06111274
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、哈尔滨、成都、武汉
- 正在招募Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- 分期
- I/II期
- 开始
- 2022-04
- 发布
- 登记号
- NCT05288205
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、厦门、合肥、哈尔滨、广州、武汉、沈阳、济南、深圳、福州、郑州、长沙
- 正在招募Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
- 分期
- III期
- 开始
- 2022-12
- 发布
- 登记号
- NCT05653453
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、哈尔滨
- 正在招募Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- 分期
- I期
- 开始
- 2021-06
- 发布
- 登记号
- NCT04900818
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州
- 即将招募A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- 分期
- II期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07623642
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文27
- TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism.
- Exploring the genetic link between gastroesophageal reflux disease and pancreatic cancer: insights from Mendelian randomization.
- The combination of gemcitabine and albumin-bound paclitaxel effectively inhibits de novo lipogenesis in pancreatic cancer cells by targeting the AMPK/SREBP1 pathway.
- Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer.
- Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.
- Age-period-cohort analysis of global, regional, and national pancreatic cancer incidence, mortality, and disability-adjusted life years, 1990-2019.
- Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy.
- VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage.
- BNIP3+ fibroblasts associated with hypoxia and inflammation predict prognosis and immunotherapy response in pancreatic ductal adenocarcinoma.
- Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.
- Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
- Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.
- Prediction scores of postoperative liver metastasis and long-term survival of pancreatic head cancer based on the distance between the mesenteric vessels and tumor, preoperative serum carbohydrate antigen 19-9 level, and lymph node metastas
- Splicing transcriptome-wide association study to identify splicing events for pancreatic cancer risk.
- HNF4G stimulates the development of pancreatic cancer by promoting IGF2BP2 transcription.
- Inhibition of autophagy promotes sonodynamic therapy-induced apoptosis of pancreatic cancer cells.
- Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase.
- Prognostic value of albumin-bilirubin score in pancreatic cancer patients after pancreatoduodenectomy with liver metastasis following radiofrequency ablation.
- The outcome of intravenous and inhalation anesthesia after pancreatic cancer resection: a retrospective study.
- HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis.
- Classification and Prognosis Analysis of Pancreatic Cancer Based on DNA Methylation Profile and Clinical Information.
- GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma.
- Determination of Deformable Image Registration Algorithms for Accumulating Dose in Carbon-ion Radiotherapy for Pancreatic Cancer.
- Silencing of FTX suppresses pancreatic cancer cell proliferation and invasion by upregulating miR-513b-5p.
- The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study.
- Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer.
- Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
- Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
- Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
- Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
- A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
- Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
- A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
- Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
癌症
乳腺癌
Breast cancer2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 168 篇,占 1.0%。
哈尔滨有 4 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下
这家医院参与的开放试验 39
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
- 分期
- II期
- 开始
- 2026-07
- 发布
- 登记号
- NCT07752550
年龄 18 岁 至 100 岁;仅女性(登记的条件)
牵头:哈尔滨医科大学附属肿瘤医院哈尔滨
- 正在招募A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
- 分期
- I/II期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07281976
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心南京、哈尔滨、广州、沈阳、郑州、长春
- 正在招募A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- 分期
- 未注明
- 开始
- 2026-01
- 发布
- 登记号
- NCT07347600
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、扬州、武汉、沈阳、济南、海口、潍坊、石家庄、西安、贵阳、郑州、重庆、长春
- 正在招募Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
- 分期
- II期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07383818
年龄 18 岁 至 70 岁;仅女性(登记的条件)
牵头:浙江大学医学院附属第一医院;另有 4 家列出的医院为研究中心上海、合肥、哈尔滨、杭州、西安
- 正在招募BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- 分期
- III期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07492641
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、汕头、海口、温州、潍坊、石家庄、福州、蚌埠、西安、郑州、重庆、长沙
- 正在招募A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- 分期
- II期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07876557
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 25 家列出的医院为研究中心兰州、北京、南京、南昌、哈尔滨、太原、广州、成都、武汉、沈阳、济南、潍坊、石家庄、福州、贵阳、郑州、银川、长春、长沙、青岛
- 正在招募A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
- 分期
- I/II期
- 开始
- 2025-01
- 发布
- 登记号
- NCT06679036
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、郑州
- 正在招募A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- 分期
- III期
- 开始
- 2025-04
- 发布
- 登记号
- NCT06790693
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心乌鲁木齐、北京、南宁、哈尔滨、天津、广州、成都、昆明、杭州、济南、襄阳、西安、长沙
- 正在招募A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- 分期
- II/III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06891833
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、南宁、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、洛阳、济南、海口、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长沙
- 正在招募A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- 分期
- III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06966700
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 21 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、合肥、哈尔滨、杭州、武汉、济南、西安、郑州、长春、长沙
- 正在招募Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06977893
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头:浙江大学医学院附属第一医院;另有 9 家列出的医院为研究中心上海、乌鲁木齐、南昌、合肥、哈尔滨、杭州、西安、郑州
- 正在招募A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- 分期
- III期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07043725
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 52 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、太原、宁波、安阳、广州、成都、新乡、梅州、武汉、汕头、沈阳、泉州、泸州、洛阳、济南、温州、潍坊、烟台、石家庄、蚌埠、衡阳、西安、贵阳、郑州、重庆、长春、长沙
- 正在招募JS207 Combination Therapy in Triple-negative Breast Cancer
- 分期
- II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07045311
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心乌鲁木齐、北京、南京、合肥、哈尔滨、大连、杭州、武汉、沈阳、石家庄、西安、郑州、长春、青岛
- 正在招募TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- 分期
- III期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07047365
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 44 家列出的医院为研究中心兰州、北京、南京、南充、南宁、南昌、合肥、哈尔滨、唐山、天津、太原、宁波、安阳、徐州、成都、新乡、昆明、沈阳、泸州、洛阳、济南、海口、深圳、温州、潍坊、石家庄、蚌埠、襄阳、西宁、西安、贵阳、郑州、重庆、长春、长沙
- 正在招募A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- 分期
- III期
- 开始
- 2025-08
- 发布
- 登记号
- NCT07062965
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、大连、广州、杭州、武汉、济南、温州、石家庄、福州、西安、长春、长沙
- 正在招募A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- 分期
- I/II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07169994
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、南京、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、梅州、沈阳、洛阳、福州、襄阳
- 正在招募A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07174336
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、哈尔滨、天津、安阳、广州、成都、武汉、汕头、福州、长春、长沙
- 正在招募An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07222267
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、厦门、哈尔滨、天津、杭州、重庆、长沙
- 正在招募Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
- 分期
- 不分期
- 开始
- 2025-10
- 发布
- 登记号
- NCT07469267
年龄 18 岁 至 未注明;仅女性(登记的条件)
牵头:复旦大学附属肿瘤医院;另有 12 家列出的医院为研究中心上海、哈尔滨、天津、宁波、杭州、武汉、济南、石家庄、贵阳、长沙
- 正在招募A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- 分期
- III期
- 开始
- 2025-01
- 发布
- 登记号
- NCT07673029
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 51 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、泉州、洛阳、济南、潍坊、烟台、石家庄、福州、蚌埠、西安、贵阳、郑州、重庆、长春、长沙、青岛
- 正在招募A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- 分期
- 未注明
- 开始
- 2024-01
- 发布
- 登记号
- NCT06210776
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、佛山、北京、南京、南昌、南通、合肥、哈尔滨、唐山、天津、太原、广州、徐州、成都、新乡、昆明、杭州、汕头、沈阳、洛阳、深圳、潍坊、珠海、福州、西安、郑州、银川、青岛
- 正在招募Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- 分期
- I/II期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06324357
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春
- 正在招募The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06452706
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、乌鲁木齐、哈尔滨、杭州、武汉、西安
- 正在招募A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
- 分期
- I期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06503783
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、哈尔滨
- 正在招募Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
- 分期
- II期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06611813
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头:浙江大学医学院附属第一医院;另有 6 家列出的医院为研究中心上海、乌鲁木齐、合肥、哈尔滨、杭州、郑州
- 正在招募Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
- 分期
- II期
- 开始
- 2024-10
- 发布
- 登记号
- NCT06682195
年龄 18 岁 至 70 岁;仅女性(登记的条件)
牵头:浙江大学医学院附属第一医院;另有 10 家列出的医院为研究中心上海、乌鲁木齐、南昌、合肥、哈尔滨、太原、杭州、西安、郑州
- 正在招募Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- 分期
- II/III期
- 开始
- 2023-09
- 发布
- 登记号
- NCT05860465
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心北京、南京、哈尔滨、天津、安阳、广州、昆明、杭州、沈阳、洛阳、石家庄、福州、蚌埠、西安、银川、长春
- 正在招募Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- 分期
- II期
- 开始
- 2023-09
- 发布
- 登记号
- NCT05872347
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头方不是列出的医院;另有 21 家列出的医院为研究中心乌鲁木齐、北京、南京、南宁、合肥、哈尔滨、天津、安阳、广州、杭州、武汉、洛阳、石家庄、蚌埠、襄阳、郑州、银川、长春
- 正在招募JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06079983
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 60 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、洛阳、济南、湛江、石家庄、福州、苏州、衡阳、襄阳、西宁、西安、贵阳、遵义、郑州、重庆、长春、长沙、青岛
- 正在招募A Study of YL202 in Selected Patients With Advanced Solid Tumors
- 分期
- II期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06107686
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛
- 正在招募BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- 分期
- I期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06120283
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、南昌、哈尔滨、广州、沈阳、福州
- 正在招募A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- 分期
- III期
- 开始
- 2022-09
- 发布
- 登记号
- NCT06954961
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨
- 正在招募Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- 分期
- IV期
- 开始
- 2021-07
- 发布
- 登记号
- NCT04136782
年龄 18 岁 至 70 岁;仅女性(登记的条件)
牵头:中国医科大学附属盛京医院;另有 3 家列出的医院为研究中心哈尔滨、沈阳、长春
- 正在招募Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
- 分期
- 未注明
- 开始
- 2021-07
- 发布
- 登记号
- NCT04476485
年龄 18 岁 至 70 岁;仅女性(登记的条件)
牵头:中国医科大学附属盛京医院;另有 3 家列出的医院为研究中心哈尔滨、沈阳、长春
- 即将招募Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
- 分期
- II期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07487519
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心哈尔滨
- 即将招募A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
- 分期
- I/II期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07560124
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、哈尔滨、成都
- 即将招募A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- 分期
- II期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07623642
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨
- 即将招募A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
- 分期
- II期
- 开始
- 2024-04
- 发布
- 登记号
- NCT06354114
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心哈尔滨
- 邀请入组A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- 分期
- II期
- 开始
- 2025-08
- 发布
- 登记号
- NCT07376629
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、南京、厦门、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、杭州、武汉、沈阳、济南、福州、苏州、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文168
- Integrating Deep Feature Extraction and MRI Radiomics for Survival Prediction in Breast Cancer After Neoadjuvant Chemotherapy.
- Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer.
- Biomimetic Organic Nanozyme as Tumor Vaccines for Targeted Suppression of Ammonia-Induced T Lymphocyte Death to Augment Breast Cancer Immunotherapy.
- Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.
- TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial.
- Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.
- Biomimetic Single-Atom Nanozyme for Dual Starvation-Enhanced Breast Cancer Immunotherapy.
- Camouflaged Nanozymes with Oxidation-Promoting Activities Triggering Ferroptosis for Radio-Immunotherapy.
- Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer.
- Lactate dehydrogenase a is a crucial biomarker that affects the prognosis, chemotherapy effect, and immune infiltration of breast cancer.
- Novel models based on machine learning to predict the prognosis of metaplastic breast cancer.
- Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.
- Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.
- An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing.
- Lnc-TPT1-AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression.
- LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.
- ZMIZ1 lactylation induces tamoxifen resistance in breast cancer through increasing transcriptional activity of Nanog to impact cell stemness and cholesterol uptake.
- In Triple-Negative Breast Cancer: Correlation Among Metabolic Syndrome, S100A7/cPLA2 Expression and the Efficacy of Neoadjuvant Chemotherapy.
- The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity.
- Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity.
- Pan-immune-inflammation value predicts survival in inflammatory breast cancer patients.
- Association of the inflammatory microenvironment of obesity with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
- Necrosis by sodium overload-associated genes TRPM4 and SLC9A1: biological roles and clinical implications in breast cancer progression.
- Integrating deep learning features from mammography with SHAP values for a machine learning model predicting over 5-year recurrence of breast ductal carcinoma In Situ post-lumpectomy.
- Association of microtubule-based processes gene expression with immune microenvironment and its predictive value for drug response in oestrogen receptor-positive breast cancer.
- Current state of cancer immunity cycle: new strategies and challenges of using precision hydrogels to treat breast cancer.
- Fundamental knowledge and research regarding the role of immunity in triple-negative breast cancer from 2014-2024: A bibliometric analysis.
- SMC4 promotes immune evasion by inhibiting endogenous interferon signaling and upregulating PD-L1 expression in triple negative breast cancer.
- Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3.
- PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway.
- HSP90 inhibitor-loaded hollow mesoporous nanoparticles for enhanced synergistic mild photothermal/chemotherapy in triple negative breast cancer.
- Molecular characterization of breast cancer and multiple primary malignancies: the latest application using unmarked quantitative proteomics.
- FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions.
- H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer.
- Machine learning-based identification of kbhb-affected tumor cell subsets as prognostic and therapeutic targets in breast cancer.
- Application of mass cytometry in the immune microenvironment of breast cancer.
- Comprehensive analysis of the biological functions and prognostic significance of GDI1 in breast cancer.
- Preoperative inflammatory status as a positive prognostic factor for triple-negative breast cancer patients receiving neoadjuvant therapy.
- Transcriptome-wide analysis reveals potential roles of CFD and ANGPTL4 in fibroblasts regulating B cell lineage for extracellular matrix-driven clustering and novel avenues for immunotherapy in breast cancer.
- Harnessing the inflammatory signature: a review for biomarkers in inflammatory breast cancer.
- Implementation of personalized multidisciplinary neuropathy management program for chemotherapy-induced peripheral neuropathy symptoms in breast cancer patients.
- Extratumoral Signs of Malignant Nonspiculate and Noncalcified Masses on Mammography: Are They Associated With Prognostic Factors in Breast Cancer?
- Cold Exposure Therapy Sensitizes Nanodrug-Mediated Radioimmunotherapy of Breast Cancer.
- Can we skip invasive biopsy of sentinel lymph nodes? A preliminary investigation to predict sentinel lymph node status using PET/CT-based radiomics.
- Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.
- Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.
- Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis.
- Diagnostic value of applying preoperative breast ultrasound and clinicopathologic features to predict axillary lymph node burden in early invasive breast cancer: a study of 1247 patients.
- Development of predictive models for pathological response status in breast cancer after neoadjuvant therapy based on peripheral blood inflammatory indexes.
- An antihypertensive drug-AT1 inhibitor attenuated BRCA development promoted by chronic psychological stress via Ang II/PARP1/FN1 pathway.
- Nanobubble-mediated co-delivery of siTRIM37 and IR780 for gene and sonodynamic combination therapy against triple negative breast cancer.
- PSAT1 Promotes Metastasis via p-AKT/SP1/ITGA2 Axis in Estrogen Receptor-Negative Breast Cancer Cell.
- Subcutaneous fat predicts bone metastasis in breast cancer: A novel multimodality-based deep learning model.
- Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients.
- Identification of Novel Anoikis-Related Gene Signatures to Predict the Prognosis, Immune Microenvironment, and Drug Sensitivity of Breast Cancer Patients.
- The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.
- Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.
- A comprehensive overview of metaplastic breast cancer: Features and treatments.
- Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.
- Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer.
- Calcium-sensing receptor and NF-κB pathways in TN breast cancer contribute to cancer-induced cardiomyocyte damage via activating neutrophil extracellular traps formation.
- The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
- Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes.
- CyTOF analysis revealed platelet heterogeneity in breast cancer patients received T-DM1 treatment.
- MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy.
- Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.
- Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.
- Integration of transcriptomics and machine learning for insights into breast cancer: exploring lipid metabolism and immune interactions.
- Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer.
- The Gustave Roussy Immune score (GRIm score) as a novel prognostic score for early breast cancer patients: A real-world retrospective study.
- RNA-Seq Reveals the Mechanism of Pyroptosis Induced by Oxygen-Enriched IR780 Nanobubbles-Mediated Sono-Photodynamic Therapy.
- TME-Responsive Nanoplatform with Glutathione Depletion for Enhanced Tumor-Specific Mild Photothermal/Gene/Ferroptosis Synergistic Therapy.
- Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis.
- Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review.
- NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction.
- Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.
- A Channel-Dimensional Feature-Reconstructed Deep Learning Model for Predicting Breast Cancer Molecular Subtypes on Overall b-Value Diffusion-Weighted MRI.
- Responds to the Comments on "A Channel-Dimensional Feature-Reconstructed Deep Learning Model for Predicting Breast Cancer Molecular Subtypes on Overall b-Value Diffusion-Weighted MRI".
- Transcription Impairment of TMEM208 by ZBTB14 Suppresses Breast cancer Radiotherapy Resistance.
- The potential of lenvatinib in breast cancer therapy.
- Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
- Clinicopathological Characteristics of Breast Cancer Patients with HER-2 Low Expression Receiving Neoadjuvant Therapy.
- The immune regulation and therapeutic potential of the SMAD gene family in breast cancer.
- Calcium-sensing Receptor, a Potential Biomarker Revealed by Large-scale Public Databases and Experimental Verification in Metastatic Breast Cancer.
- Pectoralis muscle predicts distant metastases in breast cancer by deep learning radiomics.
- Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
- Automated Breast Ultrasound (ABUS)-based radiomics nomogram: an individualized tool for predicting axillary lymph node tumor burden in patients with early breast cancer.
- The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.
- Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.
- FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.
- Albumin-bilirubin score predicts trastuzumab resistance in HER2-positive breast cancer.
- Lower subcutaneous fat index predicts bone metastasis in breast cancer.
- Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer.
- Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.
- RMI2 is a novel prognostic and predictive biomarker for breast cancer.
- Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.
- LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis.
- The effectiveness of ultrasound-guided core needle biopsy in detecting lymph node metastases in the axilla in patients with breast cancer: systematic review and meta-analysis.
- Sufentanil inhibits the metastasis and immune response of breast cancer via mediating the NF-κB pathway.
- Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab.
- Ultrasound Triggered Tumor Metabolism Suppressor Induces Tumor Starvation for Enhanced Sonodynamic Immunotherapy of Breast Cancer.
- Correlation analysis between androgen receptor and the clinicopathological features and prognosis of mammary Paget's disease.
- Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.
- Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer.
- The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier.
- Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.
- Comparison of Dynamic Contrast-Enhanced MRI and Non-Mono-Exponential Model-Based Diffusion-Weighted Imaging for the Prediction of Prognostic Biomarkers and Molecular Subtypes of Breast Cancer Based on Radiomics.
- Single-cell RNA sequencing reveals small extracellular vesicles derived from malignant cells that contribute to angiogenesis in human breast cancers.
- Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.
- Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell-derived spheres.
- The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo.
- Early Prediction of Response to Neoadjuvant Chemotherapy Using Quantitative Parameters on Automated Breast Ultrasound Combined with Contrast-Enhanced Ultrasound in Breast Cancer.
- Prediction of nonsentinel lymph node metastasis in breast cancer patients based on machine learning.
- Differences in ultrasonographic features between males and females with breast cancer of the luminal A and luminal B molecular subtypes.
- Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.
- Prediction model of axillary lymph node status using automated breast ultrasound (ABUS) and ki-67 status in early-stage breast cancer.
- Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.
- High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
- A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
- Deep learning radiomics under multimodality explore association between muscle/fat and metastasis and survival in breast cancer patients.
- Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer.
- Nano Carbon Tracing-based Treatment of Breast Cancer Lymphadenectomy and Nursing Intervention of Postoperative Lymphedema.
- LncRNA RP11-214F16.8 drives breast cancer tumorigenesis via a post-translational repression on NISCH expression.
- The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
- Value of shear wave elasticity in predicting the efficacy of neoadjuvant chemotherapy in different molecular types.
- Investigation of the Mechanism of hsa_circ_000 1429 Adsorbed miR-205 to Regulate KDM4A and Promote Breast Cancer Metastasis.
- A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
- The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy.
- Performance of novel deep learning network with the incorporation of the automatic segmentation network for diagnosis of breast cancer in automated breast ultrasound.
- Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer.
- Computer-aided classification of MRI for pathological complete response to neoadjuvant chemotherapy in breast cancer.
- Revealing the Potential Markers of N(4)-Acetylcytidine through acRIP-seq in Triple-Negative Breast Cancer.
- Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
- USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling.
- Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
- Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling.
- A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer.
- TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5.
- Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis.
- Characterized the diversity of ABCB1 subtypes in immunogenomic landscape for predicting the drug response in breast cancer.
- Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients.
- Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression.
- Prediction of Axillary Lymph Node Metastasis in Invasive Breast Cancer by Sound Touch Elastography.
- Expression and prognostic values of ARID family members in breast cancer.
- GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway.
- The application of personalized rehabilitation exercises in the postoperative rehabilitation of breast cancer patients.
- Clinical Significance of Oncoplastic Breast-Conserving Surgery and Application of Volume-Displacement Technique.
- Highly penetrating nanobubble polymer enhances LINC00511-siRNA delivery for improving the chemosensitivity of triple-negative breast cancer.
- Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
- Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.
- The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.
- HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
- Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization.
- LncRNA TINCR favors tumorigenesis via STAT3-TINCR-EGFR-feedback loop by recruiting DNMT1 and acting as a competing endogenous RNA in human breast cancer.
- Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells.
- Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.
- Nomogram Predicting the Risk of Locoregional Recurrence After Mastectomy for Invasive Micropapillary Carcinoma of the Breast.
- NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
- Caspase-3-mediated GSDME induced Pyroptosis in breast cancer cells through the ROS/JNK signalling pathway.
- Laser-triggered combination therapy by iron sulfide-doxorubicin@functionalized nanozymes for breast cancer therapy.
- N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.
- FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.
- GLUT1 participates in tamoxifen resistance in breast cancer cells through autophagy regulation.
- Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K/Akt/mTOR pathway.
- Correlations of social isolation and anxiety and depression symptoms among patients with breast cancer of Heilongjiang province in China: The mediating role of social support.
- Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.
- CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
- AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3'-diindolylmethane in human breast cancer cells.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)116
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
- Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
- Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
- Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
- A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
- A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
- Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- JS207 Combination Therapy in Triple-negative Breast Cancer
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
- A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
- A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
- A Study of YL202 in Selected Patients With Advanced Solid Tumors
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
- Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
- A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
- A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
- Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
- Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
- Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
- Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
- A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
- A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
- A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
- A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
- Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
- A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
- A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
- Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
- Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
- A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
- The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
- Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
- A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer
- A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
- Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
- Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
- Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
- Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
- Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
- A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
- A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
- Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
- Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
- Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
- A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
- Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer
- Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer
- Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
- A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
- A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
- Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
- Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
- Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer
癌症
胶质瘤
Glioma2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文14
- Targeting BACH1 by HPPE inhibits the Wnt/β-catenin pathway and malignant phenotype in glioblastoma cells.
- Role of SIX5-mediated EXO1 overexpression in driving glioblastoma progression: Insights into tumor cell migration and angiogenesis.
- Multi-omics-guided characterization of neoantigens improves patient stratification and potentiates combinatorial immunotherapy in glioma.
- Correlation of miR-3188 with patient prognosis and mechanistic inhibition of glioma proliferation, invasion, and migration by targeting MAPK1.
- Intraoperative radiotherapy in recurrent IDH-wildtype glioblastoma with gross total resection: A single-center retrospective study.
- The Relationship Between the Molecular Phenotypes of Brain Gliomas and the Imaging Features and Sensitivity of Radiotherapy and Chemotherapy.
- Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
- Reply to: Comments on "New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction".
- New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction.
- RPL34-Divergent Transcript, a Novel Long NonCoding Ribonucleic Acid, Promotes Migration by Activating Epithelial-Mesenchymal Transition in Glioma.
- Circular RNA circBFAR promotes glioblastoma progression by regulating a miR-548b/FoxM1 axis.
- GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1.
- Circular RNA circHECTD1 facilitates glioma progression by regulating the miR-296-3p/SLC10A7 axis.
- circFLNA promotes glioblastoma proliferation and invasion by negatively regulating miR‑199‑3p expression.
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 6 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文2
- A longitudinal evaluation on 3-year change of anxiety and depression, and their risk factors among parents of childhood and adolescence patients with resectable osteosarcoma: A cohort study.
- Glycogen synthase kinase 3β promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- 分期
- II/III期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07379047
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06574568
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州
- 正在招募A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- 分期
- III期
- 开始
- 2022-10
- 发布
- 登记号
- NCT05552222
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.
- Prognostic marker CD27 and its micro-environmental in multiple myeloma.
- Non-invasive discrimination of multiple myeloma using label-free serum surface-enhanced Raman scattering spectroscopy in combination with multivariate analysis.
- IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy.
- HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.
- Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Study of Ninlaro in Real World Clinical Practice in China
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 3 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 12
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- 分期
- III期
- 开始
- 2026-03
- 发布
- 登记号
- NCT07409428
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 42 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、太原、广州、徐州、成都、杭州、武汉、沈阳、泉州、济南、福州、蚌埠、西安、贵阳、郑州、重庆、长春、长沙、青岛
- 正在招募A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06742996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、临沂、北京、南京、南昌、哈尔滨、广州、徐州、成都、杭州、武汉、沈阳、温州、郑州、重庆、青岛
- 正在招募Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- 分期
- I/II期
- 开始
- 2025-04
- 发布
- 登记号
- NCT06829771
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、哈尔滨、天津、太原、广州、徐州、武汉、泉州、泸州、烟台、福州、蚌埠、西安、郑州、长春
- 正在招募Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- 分期
- II期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06854445
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 21 家列出的医院为研究中心兰州、南京、南宁、南昌、厦门、哈尔滨、大连、太原、杭州、武汉、泸州、济南、石家庄、芜湖、苏州、西安、郑州、长沙
- 正在招募A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- 分期
- III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06943872
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、呼和浩特、哈尔滨、天津、广州、成都、扬州、无锡、杭州、武汉、沈阳、济南、石家庄、福州、重庆、长沙、青岛
- 正在招募An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- 分期
- 未注明
- 开始
- 2025-09
- 发布
- 登记号
- NCT07200375
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、南昌、哈尔滨、天津、宁波、广州、成都、武汉、济南、温州、烟台、西安、郑州、长春
- 正在招募A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06566586
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、乌鲁木齐、兰州、南宁、南昌、呼和浩特、哈尔滨、天津、太原、广州、武汉、泸州、西安、郑州、长沙
- 正在招募A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT07234162
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、兰州、北京、南京、南宁、厦门、合肥、哈尔滨、天津、太原、广州、成都、杭州、武汉、沈阳、济南、温州、福州、西安、郑州、重庆、长春、长沙
- 正在招募First in Human, Dose Escalation Study of AN4005
- 分期
- I期
- 开始
- 2021-09
- 发布
- 登记号
- NCT04999384
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、哈尔滨、武汉
- 即将招募Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
- 分期
- II/III期
- 开始
- 2026-09
- 发布
- 登记号
- NCT07712588
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、哈尔滨、重庆、长沙
- 即将招募Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- 分期
- III期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07896590
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 40 家列出的医院为研究中心上海、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、海口、石家庄、福州、西安、郑州、重庆、长沙
- 即将招募Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
- 分期
- II期
- 开始
- 2025-10
- 发布
- 登记号
- NCT07206264
年龄 60 岁 至 未注明(登记的条件)
牵头:天津医科大学肿瘤医院;另有 3 家列出的医院为研究中心哈尔滨、天津、济南、福州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文26
- Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma.
- Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass.
- The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients.
- BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.
- Upregulated miR-29a-3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1.
- Effect of metabolic syndrome on prognosis in patients with peripheral T-cell lymphoma.
- Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.
- Fat mass and obesity-associated protein (FTO)-induced upregulation of flotillin-2 (FLOT2) contributes to cancer aggressiveness in diffuse large B-cell lymphoma (DLBCL) via activating the PI3K/Akt/mTOR signal pathway.
- Pyroptotic macrophages promote proliferation and chemotherapy resistance of peripheral T-cell lymphoma via TLR4 signaling pathway.
- A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma.
- The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma.
- High PPP4C expression predicts poor prognosis in diffuse large B-cell lymphoma.
- Rare Metastatic Embryonal Carcinoma Resembling Lymphoma: A Case Report.
- Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
- Joint Analysis of CCAAT/Enhancer-Binding Protein Beta and Interleukin 1 Beta in the Treatment and Prognosis of Diffuse Large B-Cell Lymphoma.
- Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
- Development and validation of a [18F]FDG PET/CT-based radiomics nomogram to predict the prognostic risk of pretreatment diffuse large B cell lymphoma patients.
- Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.
- A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.
- MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway.
- A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.
- Diagnosis and staging of diffuse large B-cell lymphoma using label-free surface-enhanced Raman spectroscopy.
- High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
- Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.
- Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.
- Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)44
- A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
- An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- First in Human, Dose Escalation Study of AN4005
- Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
- A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
- A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
- Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
- BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
- A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
- Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
- A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
- Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma
- Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
- Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
- A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年没有牵头范可尼贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
早期论文(2016–2020 年)5
- Triptolide inhibits tonsillar IgA production by upregulating FDC-SP in IgA nephropathy.
- Analysis of microbial changes in the tonsillar formalin-fixed paraffin-embedded tissue of Chinese patients with IgA nephropathy.
- Tonsillar immunology in IgA nephropathy.
- IgA nephropathy and renal cell carcinoma: molecular genetic analysis.
- Thymic stromal lymphopoietin in tonsillar follicular dendritic cells correlates with elevated serum immunoglobulin A titer by promoting tonsillar immunoglobulin A class switching in immunoglobulin A nephropathy.
联系这家医院
出示给工作人员或司机的院名卡
哈尔滨医科大学附属肿瘤医院
Harbin Medical University Cancer Hospital
哈尔滨
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药